
GSK (GSK LN) Q4 (GBP): Revenue 8.1bln (exp. 8.05bln), Core EPS 0.23 (exp. 0.43). FY24: Sales 31.38bln (exp. 31.2bln), adj. EPS 1.59 (exp. 1.55), adj. Operating Profit 9.15bln (exp. 8.3bln). GBP 2bln buyback over the next 12-months.
FY Outlook
- Core Operating Profit growth 6-8%
- Turnover growth 3-5%
- Core EPS growth 6-8%
Long Term Outlook (2031)
- Revenue 40bln (prev. guided >38bln)
Analysis details (07:05)
- Investor call at 10:45GMT.
05 Feb 2025 - 07:00- EquitiesImportant- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts